Quaternion Gravi-Electromagnetism

Defining the generalized charge, potential, current and generalized fields as complex quantities where real and imaginary parts represent gravitation and electromagnetism respectively, corresponding field equation, equation of motion and other quantum equations are derived in manifestly covariant manner. It has been shown that the field equations are invariant under Lorentz as well as duality transformations. It has been shown that the quaternionic formulation presented here remains invariant under quaternion transformations.Comment: Key Words: Quaternion, dyons, gravito-dyons, gravi-electromagnetism. PACS No.: 04.90. +e ; 14.80. H

Unified Angular Momentum of Dyons

Unified quaternionic angular momentum for the fields of dyons and gravito-dyons has been developed and the commutation relations for dynamical variables are obtained in compact and consistent manner. Demonstrating the quaternion forms of unified fields of dyons (electromagnetic fields) and gravito-dyons (gravito-Heavisidian fields of linear gravity), corresponding quantum equations are reformulated in compact, simpler and manifestly covariant way

Development and integration of soil moisture sensor with drip system for precise irrigation scheduling through mobile phone

Soil moisture sensor is an instrument for quick measurements of soil moisture content in the crop root zone on real time basis. The main objective of this research was development and evaluation of an indigenous sensor for precise irrigation scheduling. The various parts of sensor developed were ceramic cup, acrylic pipe, level sensor, tee, reducer, gland, cork, and end cap. The designed system was successfully tested on okra crop and calibrated with frequency domain reflectometry (FDR) by three methods of irrigation, i.e. check basin, furrow and drip, respectively. The average depth of water depletion in modified tensiometer by these methods was 27 to 35 cm at 50% management allowable depletion (MAD) of field capacity. This depth was useful for the level sensor to be installed inside modified tensiometer for real time irrigation scheduling. The correlation coefficient (R2) between soil moisture content obtained from the developed sensor and FDR was 0.963. Sensor network was integrated with global system for mobile communication (GSM), short message service (SMS) and drip head work to develop an automated irrigation system. This would enable farmers to effectively monitor and control water application in the field by sending command through SMS and receiving pumping status through the mobile phone

The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited

BACKGROUND: To compare a near decade of follow-up, newer control cohort data, use of both the societal and third party insurer cost perspectives, and integration of unilateral/bilateral therapy on the comparative effectiveness and cost-effectiveness of intravitreal ranibizumab therapy for neovascular, age-related macular degeneration (AMD). METHODS: Value-Based Medicine(®), 12-year, combined-eye model, cost-utility analysis employing MARINA and HORIZON clinical trial data. Preference-based comparative effectiveness outcomes were quantified in (1) QALY (quality-adjusted life-year) gain, and (2) percent improvement in quality-of-life, while cost-effectiveness outcomes were quantified in (3) the cost-utility ratio (CUR) and financial return-on-investment (ROI) to society. RESULTS: Using MARINA and HORIZON trial data and a meta-analysis control cohort after 24 months, ranibizumab therapy conferred a combined-eye patient value (quality-of-life) gain of 16.3%, versus 10.4% found in 2006. The two-year direct ophthalmic medical cost for ranibizumab therapy was $46,450, a 33.8$242,920/QALY, indicating a $282,517 financial return-on-investment (ROI), or 12.3$21,199/QALY utilizing all direct, medical costs, to $69,591/QALY using direct ophthalmic medical costs. CONCLUSIONS: Ranibizumab therapy for neovascular AMD in 2015, considering treatment of both eyes, conferred greater patient value gain (comparative effectiveness) and improved cost-effectiveness than in 2006, as well as a large monetary return-on-investment to the Gross Domestic Product and nation’s wealth. The model herein integrates important novel features for neovascular age-related macular degeneration, vitreoretinal cost effectiveness analyses, including: (1) treatment of both eyes, (2) a long-term, untreated control cohort, and (3) the use of societal costs